Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study
Abstract
Objective: To investigate the safety and efficacy of anlotinib hydrochloride capsules in stage III–IV non-small-cell lung cancer (NSCLC). Methods: NSCLC patients received anlotinib monotherapy or combination therapy. The primary end point was adverse reactions during anlotinib treatment and the secondary end point was progression-free survival. Results: During anlotinib treatement, 41.85% (167/399) of patients experienced adverse reactions, and the monotherapy group had a lower incidence than the combination group (36.89 vs 49.68%; p = 0.012). The median progression-free survival of patients in the monotherapy group was significantly lower than that in the combination group (5 vs 6 months; p = 0.0119). Conclusion: Compared with anlotinib monotherapy, combination therapy resulted in longer PFS and a higher incidence of adverse reactions in patients with NSCLC.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.) 134(7), 783–791 (2021).
- 2. . Lung cancer in China: current and prospect. Curr. Opin. Oncol. 33(1), 40–46 (2021).
- 3. . Non-small cell lung cancer in China. Cancer Commun. (Lond.) 42(10), 937–970 (2022).
- 4. . Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit. Rev. Oncol. Hematol. 157,
doi:10.1016/j.critrevonc.2020.103194 (2021) (Epub ahead of print). - 5. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125), 1023–1075 (2018).
- 6. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J. Thorac. Oncol. 11(12),2112–2119 (2016).
- 7. . Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance.Annu. Rev. Pathol. 16, 223–249 (2021)
- 8. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 19(2), 75–90 (2022).
- 9. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 11(1), 120 (2018).
- 10. . Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene 654, 77–86 (2018).
- 11. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res. 38(1), 71 (2019).
- 12. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur. Respir. J. 53(3),
doi:10.1183/13993003.01562-2018 (2019) (Epub ahead of print). - 13. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell. Death Dis. 11(7), 573 (2020).
- 14. . Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. Cancer Chemother. Pharmacol. 89(2), 183–196 (2022).
- 15. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist 24(8), e702–e708 (2019). • Comparing the clinical efficacy of anlotinib versus sunitinib as a first-line drug treatment for malignant tumors, and has reference significance for the treatment of lung cancer.
- 16. Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib. Pediatr. Surg. Int. 38(3), 465–472 (2022). • The antitumor activities of anlotinib, oxaliplatin and sorafenib are compared in animal models to provide a reference for in-depth understanding of the antitumor molecular mechanism of anlotinib.
- 17. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncol. 10(13), 2081–2096 (2014). • A review of the research progress of third- and fourth-line clinical treatment in patients with advanced non-small-cell lung cancer.
- 18. . Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option? Oncology 77(Suppl. 1), S113–S121 (2009).
- 19. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4(11), 1569–1575 (2018). •• A previous study investigating the clinical efficacy of anlotinib as a third-line or subsequent drug for lung cancer.
- 20. et al. The efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study. Cancer Manag. Res. 14, 2273–2287 (2022). •• A recently published study exploring the clinical efficacy of anlotinib in the treatment of non-small-cell lung cancer in a real-world, multicenter study.
- 21. . Antiangiogenic therapies in non-small-cell lung cancer. Curr. Oncol. 25(Suppl. 1), S45–S58 (2018).
- 22. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: results of the IFCT-1103 ULTIMATE study. Eur. J. Cancer 131, 27–36 (2020).
- 23. . Cost–effectiveness of osimertinib vs docetaxel-bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China. Clin. Ther. 42(11), 2159–2170.e6 (2020).
- 24. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis. Fron. Oncol. 13,
doi:10.3389/fonc.2023.1095362 (2023) (Epub ahead of print). • A recently published study exploring the clinical efficacy and adverse effects of anlotinib in the treatment of high-grade glioma carcinoma. - 25. . Anlotinib-induced hypertension: current concepts and future prospects. Curr. Pharm. Des. 28(3), 216–224 (2022). • A study of anlotinib treatment of induced hypertension.
- 26. et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol. 9(1), 105 (2016). •• A study of anlotinib in the treatment of solid tumors, including clinical efficacy, adverse effects, pharmacokinetics and antitumor mechanisms.